keyword
MENU ▼
Read by QxMD icon Read
search

Telbivudine

keyword
https://www.readbyqxmd.com/read/29625557/case-report-lactic-acidosis-and-rhabdomyolysis-during-telbivudine-and-tenofovir-treatment-for-chronic-hepatitis-b
#1
Yue Ying, Yue-Kai Hu, Jia-Lin Jin, Ji-Ming Zhang, Wen-Hong Zhang, Yu-Xian Huang
BACKGROUND: Current treatment options for chronic hepatitis B (CHB) are pegylated interferon alpha and nucleoside analogues (NAs). NAs have relatively fewer side effects than interferon alpha, and generally well tolerated. Previously 12.9% of patients on telbivudine treatment were reported to develop severe elevation of serum creatine phosphokinase (CPK) levels, but related clinical disease, like lactic acidosis (LA) and rhabdomyolysis (RM) were rare. The pathophysiology may be mitochondrial toxicity, for the NAs inhibit not only hepatitis B virus (HBV) polymerase, but also the host mitochondrial DNA polymerase γ...
April 6, 2018: BMC Gastroenterology
https://www.readbyqxmd.com/read/29611400/real-world-experience-of-telbivudine-versus-entecavir-in-patients-with-chronic-hepatitis-b-including-long-term-outcomes-after-treatment-modification
#2
Jong Won Choi, Se Hyun Kim, Jeong Hun Seo, Yong Suk Cho, Sun Young Won, Byung Kyu Park, Han Ho Jeon, Yong Kang Lee, Chun Kyon Lee
PURPOSE: To estimate long-term outcomes after treatment modification in patients with chronic hepatitis B (CHB) treated with entecavir (ETV) and telbivudine (LdT). MATERIALS AND METHODS: The study enrolled 131 nucleos(t)ide analogue (NA)-naïve CHB patients treated with ETV or LdT. During the 3-year study, NA treatment history including the incidence, the type of treatment modification, reasons for the modification, and overall complete virologic response (CVR) rate were retrospectively evaluated using the patients' medical records...
May 2018: Yonsei Medical Journal
https://www.readbyqxmd.com/read/29577027/upgrade-combination-response-is-limited-by-prolonged-nucelos-t-ide-analogue-therapy-in-hbeag-positive-chronic-hepatitis-b-a-real-life-study
#3
Qiaohe Wang, Hu Li, Daohai Ding, Mingli Peng, Hong Ren, Peng Hu
Background and Aims: Few previous studies have reported on a combination response (hepatitis B virus (HBV) DNA undetected, alanine aminotransferase normalization and hepatitis B e antigen (HBeAg) seroconversion) following nucleos(t)ide analogue (NAs) long-term therapy in patients with chronic hepatitis B (CHB). This study aimed to investigate the combination response on long-term NAs therapy in patients with HBeAg-positive CHB and to determine whether prolonged therapy is beneficial for combination response, particularly in optimal patients (baseline alanine aminotransferase level ≥5 upper limit of normal and HBV DNA level <109 copies/mL)...
March 28, 2018: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/29570939/telbivudine-associated-mitochondrial-myopathy
#4
Su-Shen Lim, Hsien-Tzung Liao, Chang-Youh Tsai
A 62-year-old male had a history of hepatitis B virus infection with fulminant hepatitis status post liver transplant in 2 years ago presented to Rheumatology clinic with one-year history of progressive proximal muscle weakness of bilateral lower extremities. He had difficulty in climbing stairs or standing up from squatting and easily choking. His maintenance medications after liver transplant included tacrolimus and telbivudine for chronic hepatitis B viral infection1 . This article is protected by copyright...
March 23, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29545185/title-prophylaxis-for-hepatitis-b-virus-reactivation-after-allogeneic-stem-cell-transplantation-in-the-era-of-drug-resistance-and-newer-antivirals-a-systematic-review-and-meta-analysis
#5
Aida Siyahian, Saad Ullah Malik, Adeela Mushtaq, Carol L Howe, Aneela Majeed, Tirdad Zangeneh, Samar Iftikhar, Shahid Habib, Umar Zahid, Irbaz Bin Riaz, Zabih Warraich, Warda Faridi, Faiz Anwer
Patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) are at a very high risk of hepatitis B virus reactivation (HBVr). Lamivudine is commonly used as prophylaxis against HBVr in high risk patients undergoing allo-HSCT. Unfortunately, its efficacy is diminishing due to the development of HBV mutant drug resistant strains. With the availability of newer antiviral agents like Entecavir, Telbivudine, Adefovir and Tenofovir, it is important to assess their role in HBVr prophylaxis. A comprehensive search of seven databases was performed to evaluate efficacy of antiviral prophylaxis against HBVr in allo-HSCT patients (PubMed/Medline, Embase, Scopus, Cochrane Library, Web of Science, CINAHL, and ClinicalTrials...
March 12, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29505905/effects-of-treatment-of-chronic-hbv-infection-on-patient-reported-outcomes
#6
Zobair M Younossi, Maria Stepanova, Harry L A Janssen, Kosh Agarwal, Mindie H Nguyen, Ed Gane, Naoky Tsai, Issah Younossi, Andrei Racila
BACKGROUND AND AIM: Chronic infection with hepatitis B virus (HBV) causes liver disease and cirrhosis. It is not clear how treatment of chronic HBV infection affects patient-reported outcomes (PROs). We aimed to assess changes in PROs in patients treated for chronic HBV infection. METHODS: We collected and analyzed PRO data from 242 patients with chronic HBV infection (without advanced fibrosis or cirrhosis) enrolled in 2 international phase 2 blinded controlled clinical trials from 2015 through 2017...
March 2, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29489662/motor-development-delay-in-offspring-is-associated-with-prenatal-telbivudine-exposure
#7
Chengliang Zhou, Ying Yu, Qian Yang, Huihui Wang, Min Hou, Li Jin, Fanghong Zhang, Jiangzhong Sheng, Mingfang Miao, Xiaofu Yang, He-Feng Huang
Telbivudine is an orally nucleoside analog with potent and specific antihepatitis B virus (HBV) activity, and it has been reported to block mother-to-infant transmission. However, few studies have focused on the safety of prenatal exposure for offspring development.This is a prospective noninterventional study. Participants were enrolled during delivery through the Women's Hospital of Zhejiang University School of Medicine between January 2012 and September 2013. Neonate's umbilical cord arterial blood (UCAB) was collected after delivery...
March 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29453915/efficacy-of-nucleoside-analogues-for-hepatitis-b-virus-related-liver-failure-a-network-meta-analysis
#8
Jian Wu, Fang Yin, Xinmin Zhou
The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two- and three-month survival rate was recorded for patients using tenofovir...
March 1, 2018: Acta Pharmaceutica
https://www.readbyqxmd.com/read/29438889/recent-progress-in-potential-anti-hepatitis-b-virus-agents-structural-and-pharmacological-perspectives
#9
REVIEW
Dejuan Sun, Lingjuan Zhu, Dahong Yao, Lixia Chen, Leilei Fu, Liang Ouyang
Hepatitis B virus (HBV) infections affect about 240 million patients worldwide and increase the risk of liver cirrhosis and hepatocellular carcinoma. It is estimated that about 686 thousand people died annually of liver damage resulted from HBV infections. At present, two classes of antiviral drugs have been approved by the Food and Drug Administration (FDA) for the treatment of hepatitis B, immunomodulators (interferon [IFN]-a and pegylated-interferon [PEG-IFN]-a) and nucleos(t)ide analogs (lamivudine, telbivudine, adefovir, tenofovir [TDF], and entecavir [ETV])...
March 10, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29378384/-diagnosis-and-therapy-of-hepatitis-b-virus-infection-czech-national-guidelines
#10
Petr Husa, Jan Šperl, Petr Urbánek, Soňa Fraňková, Stanislav Plíšek, Petr Kümpel, Luděk RoŽnovský
The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September 2014. The basis for these guidelines were the European Association for the Study of the Liver guidelines from April 2017. According to qualified estimates, there are 240 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to the latest seroprevalence study, 0.56 % of the Czech citizens were chronically infected with HBV in 2001...
December 2017: Klinická Mikrobiologie a Infekc̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29362723/durability-of-telbivudine-associated-improvement-of-renal-function-following-withdrawal-or-switching-of-antivirals-in-chronic-hepatitis-b-patients
#11
Chao-Wei Hsu, Yi-Cheng Chen, Ming-Ling Chang, Chen-Chun Lin, Shi-Ming Lin, Wei-Ting Chen, Yu-De Chu, Chau-Ting Yeh
Background: Besides antiviral activities against hepatitis B virus (HBV), telbivudine has an extrahepatic pharmaceutical effect: to improve renal function assessed by estimated glomerular filtration rate (eGFR). However, the durability of this effect after withdrawal of telbivudine or switching to other antivirals has never been investigated. Methods: We conducted a postmarketing, real-world observation study for telbivudine treatment. The durability of telbivudine-associated renal function improvement was examined following withdrawal/switching of antivirals...
January 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29359487/review-article-long-term-safety-of-oral-anti-viral-treatment-for-chronic-hepatitis-b
#12
REVIEW
G L-H Wong, W-K Seto, V W-S Wong, M-F Yuen, H L-Y Chan
BACKGROUND: Safety profile of nucleos(t)ide analogues is an important issue in view of its widespread use for decades in patients with chronic hepatitis B (CHB). AIM: To review and evaluate the latest evidence on the safety profiles of the six approved nucleoside analogues. METHODS: Relevant articles related to nucleoside analogue safety were selected for review following extensive language- and date-unrestricted, electronic searches of the literature...
March 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29344772/safety-and-efficacy-of-lamivudine-or-telbivudine-started-in-early-pregnancy-for-mothers-with-active-chronic-hepatitis-b
#13
Tianyu He, Yuqing Bai, Haodong Cai, Xiaojuan Ou, Min Liu, Wei Yi, Jidong Jia
BACKGROUND: Few data exist regarding use of nucleos(t)ide analogs started in early pregnancy for mothers with active chronic hepatitis B (CHB). We assessed the safety and efficacy of lamivudine/telbivudine initiated in the first trimester versus no treatment in mothers with active CHB. METHODS: We retrospectively enrolled 94 mothers newly diagnosed with active CHB in the first trimester of pregnancy. Patients with or without antiviral therapy were followed until postpartum week 28...
January 17, 2018: Hepatology International
https://www.readbyqxmd.com/read/29325289/-optimal-treatment-regimen-for-patients-with-hbeag-positive-chronic-hepatitis-b-after-suboptimal-response-to-24-weeks-of-peg-ifn-%C3%AE-2a
#14
X D Luo, X P Chen, X F Chen
Objective: To investigate the optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B (CHB) after suboptimal response to 24 weeks of pegylated interferon (Peg-IFN) α-2a. Methods: A total of 188 patients with HBeAg-positive CHB who had suboptimal response to 24 weeks of Peg-IFN α-2a were randomly divided into entecavir group ( n = 93) and telbivudine group ( n = 95). The two groups received entecavir 0.5 mg/d and telbivudine 0.6 g/d, respectively, for 208 weeks. After 208 weeks of treatment, the following indices were assessed: HBeAg clearance rate and seroconversion rate, hepatitis B virus (HBV) DNA clearance rate (HBV DNA < 500 IU/ml), safety, and drug resistance rate...
December 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29274174/prophylactic-antiviral-therapy-for-the-prevention-of-mother-to-child-transmission-of-hepatitis-b-virus-can-be-stopped-at-delivery
#15
LETTER
Q-L Zeng, G-H Xu, B Wang, Z-Q Li, Z-J Yu
No abstract text is available yet for this article.
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29207359/telbivudine-attenuates-uuo-induced-renal-fibrosis-via-tgf-%C3%AE-smad-and-nf-%C3%AE%C2%BAb-signaling
#16
Jie Chen, Detian Li
Renal fibrosis yields decreased renal function and is a potent contributor to chronic kidney disease (CKD). Telbivudine (LdT) is an anti-hepatitis B virus (HBV) drug that has been found to steadily improve renal function, but the mechanism of drug action is unclear. One explanation is that LdT impacts inflammatory or fibrotic pathways. In this study, we investigated renal protection by LdT in a rat model of unilateral ureteral obstruction (UUO). UUO rats received oral gavage of LdT (1, 1.5, or 2g/kg/day) for 5weeks...
February 2018: International Immunopharmacology
https://www.readbyqxmd.com/read/29193547/safety-and-efficacy-of-telbivudine-in-late-pregnancy-to-prevent-mother-to-child-transmission-of-hepatitis-b-virus-a-multicenter-prospective-cohort-study
#17
Y Hu, C Xu, B Xu, L Hu, Q Liu, J Chen, J Liu, L Liu, J Yang, T Chen, J Wen, N Jiang, Y Zhang, M Cao, J Feng, X Lin, Z Wang, B Xu, Y-H Zhou
Infection of hepatitis B virus (HBV) occurs in ~10% of infants of HBV-infected mothers with positive hepatitis B e antigen (HBeAg) after immunoprophylaxis. We aimed to evaluate the safety and efficacy of telbivudine used during late pregnancy for preventing mother-to-child transmission of HBV. We conducted a multicenter prospective cohort study in 5 hospitals from 2012 to 2014, which enrolled HBV-infected singleton pregnant women with positive HBeAg. By their choice, women were divided into therapy (telbivudine 600 mg/day, from gestation 28-32 weeks to 3-4 weeks postpartum) and control (no antiviral agent) groups...
November 28, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29193536/temporal-trend-and-risk-determinants-of-hepatocellular-carcinoma-in-chronic-hepatitis-b-patients-on-entecavir-or-tenofovir
#18
Yao-Chun Hsu, Hsiu-J Ho, Teng-Yu Lee, Yen-Tsung Huang, Ming-Shiang Wu, Jaw-Town Lin, Chun-Ying Wu, Hashem B El-Serag
This study aimed to elucidate the temporal change and determinants for the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B continuously receiving nucleos(t)ide analogues. Through analysis of the national healthcare database in Taiwan, we screened a total of 65,426 infected patients receiving entecavir or tenofovir for at least 3 months and excluded those with lamivudine, adefovir or telbivudine exposure, malignancy, end-stage renal failure, or a diagnosis of HCC within 3 months of starting treatment...
November 28, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29179767/rhabdomyolysis-lactic-acidosis-and-multiple-organ-failure-during-telbivudine-treatment-for-hepatitis-b-a-case-report-and-review-of-the-literature
#19
Jinxin Zheng, Minggui Deng, Xiaoliang Qiu, Zhong Chen, Duoyun Li, Xiangbin Deng, Qiwen Deng, Zhijian Yu
BACKGROUND: Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, and lactic acidosis. However, reported cases of telbivudine leading to multiple organ failure are rare. Here, we report a case of telbivudine-induced severe polymyositis, lactic acidosis, and multiple organ failure. CASE PRESENTATION: A 30-year-old Chinese man with hepatitis B virus infection received antiviral treatment with 600 mg of telbivudine daily for more than 11 months...
November 27, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29148589/determination-of-telbivudine-in-the-plasma-of-chronic-hepatitis-b-patients-in-long-term-treatment-by-high-performance-liquid-chromatographic-tandem-mass-spectrometry
#20
Bicui Chen, Li Chen, Cai Cheng, Mingkang Zhong, Xiaojin Shi, Jiming Zhang, Bin Wang
Creatine kinase elevation is commonly reported in telbivudine-treated patients. However, little is known about the relationship between this adverse drug reaction and plasma concentration. In this study, a sensitive, rapid and safe quantitative bioanalytical method has been established by using LC-MS/MS for the determination of telbivudine in a clinical study of chronic hepatitis B patients. The assay was linear in a dynamic 10-10,000 ng/mL range (r2 > 0.999) and total analysis time was 6 min in this method...
April 2018: Biomedical Chromatography: BMC
keyword
keyword
2108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"